
Target Temperature Management (TTM) after cardiac arrest trial
The brain of a patient resuscitated after cardiac arrest (CA) may have suffered ischaemia and when the spontaneous circulation is re-established, the subsequent reperfusion may cause further damage.
Brain ischaemia and the reperfusion injury lead to tissue degeneration and loss of neurological function, the extent dependent on duration and density of the insult. Temperature control and mild induced hypothermia (MIH) (33-36°C) mitigate this damage in the experimental setting and clinical trials have shown promising results in improving neurological function and survival.
The TTM trial is an investigator-initiated, multicentre, international, randomised trial with 1:1 concealed allocation of OHCA patients to target temperature managements of 33°C or 36°C for 24 hours, with blinded outcome evaluation.
Aims
The primary aim of the TTM trial is to evaluate whether there is a difference in survival with a target temperature of 33°C compared to a target temperature of 36°C, in patients unconscious after an out-of-hospital cardiac arrest (OHCA).
Status
The TTM trial finished recruiting in January 2013. Results were released in November 2013 and the study has now completed.
Leads
Related People
-
Niklas Nielsen
Sweden -
Tobias Cronberg
Lund University Hospital -
David Erlinge
Lund University Hospital -
Hans Friberg
Lund University Hospital -
Christian Hassager
Copenhagen University Hospital -
Janneke Horn
Amsterdam Academic Medical Centre -
Jan Hovdenes
Oslo University Hospital -
Jesper Kjaergaard
Copenhagen University Hospital -
Michael Kuiper
Leeuwarden Hospital -
Yvan Gasche
-
Thomas Pellis
Pordenone -
Pascal Stammet
Leeuwarden Hospital -
Michael Wanscher
Copenhagen University Hospital -
Jørn Wetterslev
Copenhagen Trial Unit -
Matthew Wise
University Hospital of Wales -
Anders Aneman
Liverpool Hospital -
Gill Bishop
Campbelltown Hospital